司来吉兰联合盐酸金刚烷胺治疗帕金森病患者的临床效果分析

Clinical Effect Analysis of Selegiline Combined with Amantadine Salt in the Treatment of Parkinson's Disease Patients

目的探索司来吉兰联合盐酸金刚烷胺治疗帕金森病患者的实际临床效果并进行安全性评价。方法随机选取宿迁市沭阳仁慈医院于2021年1月—2023年1月收治的94例帕金森病患者为研究对象,采用随机数表法分为对照组及观察组,各47例。对照组给予司来吉兰治疗,观察组在对照组基础上给予盐酸金刚烷胺治疗,均持续治疗6个月。比较两组患者临床治疗有效率,多巴胺、5-羟色胺、脑源性神经营养因子水平及不良反应发生率。结果观察组治疗有效率为82.98%,高于对照组的63.83%,差异有统计学意义(P<0.05);治疗后,观察组血清多巴胺、5-羟色胺、脑源性神经营养因子水平均高于对照组,差异有统计学意义(P均<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论司来吉兰联合盐酸金刚烷胺可显著改善患者临床症状、提升生活质量水平,并具有一定的安全性。

Objective To explore the clinical effect and safety of Selegiline combined with amantadine in the treatment of patients with Parkinson's disease.Methods A total of 94 patients with Parkinson's disease treated in Shuyang Renren Hospital of Suqian City from January 2021 to January 2023 were selected as the study objects,and were divided into control group and observation group by random number table method,with 47 patients in each group.The control group was treated with Selegiline,and the observation group was treated with amantadine hydrochloride on the basis of the control group,and the treatment lasted for 6 months.The effective rate of clinical treatment,the changes of dopamine,5-hydroxytryptamine and brain-derived neurotrophic factor concentrations and the incidence of adverse reactions were compared between the two groups.Results The effective rate of the observation group was 82.98%,which was higher than that of the control group(63.83%),the difference was statistically significant(P<0.05).After treatment,the serum concentrations of dopamine,5-hydroxytryptamine and brain-derived neurotrophic factor in observation group were higher than those in control group,and the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Selegiline combined with amantadine salt can significantly improve the clinical symptoms and improve the quality of life of patients,and has certain safety.